AKRO

37.63

0.51% 0.19

Dopo l'orario di chiusura: 37.63

Akero Therapeutics Inc (AKRO)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché AKRO Giù? Forum Previsione

Precedente Chiudi:

$37.44

Aprire:

$37.09

Volume 24 ore:

521.58K

Relative Volume:

0.38

Capitalizzazione di mercato:

$2.99B

Reddito:

Utile/perdita netta:

$-237.22M

Rapporto P/E:

-9.955

EPS:

-3.78

Flusso di cassa netto:

$-212.64M

1 W Prestazione:

+8.07%

1M Prestazione:

-16.04%

6M Prestazione:

+22.10%

1 anno Prestazione:

+74.21%

Intervallo 1D:

$36.67

$37.85

Intervallo di 1 settimana:

$34.18

$39.13

Portata 52W:

$17.86

$58.40

Akero Therapeutics Inc Stock (AKRO) Company Profile

Nome

Akero Therapeutics Inc

Settore

Healthcare (1151)

Industria

Biotechnology (660)

Telefono

650-487-6488

Indirizzo

601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA

Dipendente

Cinguettio

@akerotx

Prossima data di guadagno

2024-11-11

Ultimi documenti SEC

AKRO's Discussions on Twitter

Confronta AKRO con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
AKRO Akero Therapeutics Inc	37.63	2.99B	0	-237.22M	-212.64M	-3.78
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-01-30	Aggiornamento	BofA Securities	Neutral → Buy
2025-01-27	Reiterato	H.C. Wainwright	Buy
2024-11-18	Iniziato	Citigroup	Buy
2024-04-22	Ripresa	BofA Securities	Neutral
2023-09-19	Iniziato	Cantor Fitzgerald	Overweight
2023-08-28	Iniziato	UBS	Buy
2023-01-27	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2022-09-14	Aggiornamento	Evercore ISI	In-line → Outperform
2021-10-19	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-09-10	Iniziato	BofA Securities	Buy
2021-02-26	Iniziato	Guggenheim	Buy
2020-09-10	Iniziato	Morgan Stanley	Overweight
2020-07-20	Reiterato	H.C. Wainwright	Buy
2020-07-07	Iniziato	Chardan Capital Markets	Buy
2020-07-01	Reiterato	H.C. Wainwright	Buy
2020-03-02	Iniziato	H.C. Wainwright	Buy
2020-02-10	Iniziato	Canaccord Genuity	Buy
2019-07-15	Iniziato	Evercore ISI	Outperform
2019-07-15	Iniziato	JP Morgan	Overweight
2019-07-15	Iniziato	Jefferies	Buy
2019-07-15	Iniziato	ROTH Capital	Buy

Mostra tutto

Akero Therapeutics Inc Borsa (AKRO) Ultime notizie

Apr 16, 2025

F M Investments LLC Takes Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Apr 16, 2025

JPMorgan Chase & Co. Acquires 40,161 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Apr 16, 2025

Akero Therapeutics chief development officer sells $343,962 in shares By Investing.com - Investing.com India

Apr 16, 2025

Akero Therapeutics chief development officer sells $343,962 in shares - Investing.com

Apr 16, 2025

Geode Capital Management LLC Sells 11,381 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Apr 16, 2025

Apr 15, 2025

Sei Investments Co. Takes Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Apr 15, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out - markets.businessinsider.com

Apr 15, 2025

University of Wisconsin Foundation Sells 13,219 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Apr 15, 2025

Optimize Financial Inc Buys New Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Apr 15, 2025

ExodusPoint Capital Management LP Has $1.54 Million Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Apr 15, 2025

Apr 14, 2025

Vanguard Group Inc. Has $103.06 Million Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Apr 14, 2025

Apr 13, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Connect - markets.businessinsider.com

Apr 13, 2025

JPMorgan Chase & Co. Increases Stock Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World

Apr 13, 2025

Apr 12, 2025

Schroder Investment Management Group Sells 158,817 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Apr 12, 2025

Apr 11, 2025

Akero therapeutics CEO Andrew Cheng sells $1.06 million in stock - Investing.com

Apr 11, 2025

Sei Investments Co. Makes New Investment in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World

Apr 11, 2025

Springhill Fund Asset Management HK Co Ltd Takes $4.21 Million Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Apr 11, 2025

Apr 10, 2025

Akero therapeutics chief scientific officer sells $224,261 in stock By Investing.com - Investing.com South Africa

Apr 10, 2025

11,000 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Bought by KLP Kapitalforvaltning AS - MarketBeat

Apr 10, 2025

Akero therapeutics chief scientific officer sells $224,261 in stock - Investing.com

Apr 10, 2025

American Century Companies Inc. Has $3.13 Million Stake in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Apr 10, 2025